Co-Authors
This is a "connection" page, showing publications co-authored by Timothée Klopfenstein and Pierre-Yves Royer.
Connection Strength
2.865
-
Angioedema and COVID-19: A New Dermatological Manifestation? Infect Dis Rep. 2021 Jan 01; 13(1):23-25.
Score: 0.922
-
Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France. Microorganisms. 2021 Aug 12; 9(8).
Score: 0.240
-
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia. Infect Dis Ther. 2021 Sep; 10(3):1195-1213.
Score: 0.239
-
Recurrence of COVID-19 after recovery ? A case series in health care workers, France. Microbes Infect. 2021 May-Jun; 23(4-5):104803.
Score: 0.233
-
Comparison of COVID-19 and influenza in adult patients: Neurological symptoms input. J Med Virol. 2021 04; 93(4):1893-1895.
Score: 0.230
-
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct; 99:491-495.
Score: 0.224
-
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. Int J Infect Dis. 2020 Nov; 100:117-122.
Score: 0.224
-
Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect. 2020 10; 22(9):481-488.
Score: 0.222
-
Diarrhea: An underestimated symptom in Coronavirus disease 2019. Clin Res Hepatol Gastroenterol. 2020 06; 44(3):282-283.
Score: 0.220
-
Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):742-747.
Score: 0.056
-
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes Infect. 2020 10; 22(9):500-503.
Score: 0.056